Welcome to the e-CCO Library!

P646: Refinement of surgical technique offsets increased severity of Crohn’s disease and co-morbidities to maintain low post-operative morbidity
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Mege1,2*, K. Garrett1, J. Milsom1, T. Sonoda1, F. Michelassi1

Created: Thursday, 21 February 2019, 9:14 AM
P646: The Loss of Productivity in Employment and Education Associated to Inflammatory Bowel Diseases: A Pilot Study of the Patient’s Perception
Year: 2021
Source: ECCO'21 Virtual
Authors: Nieves-Jimenez, H.(1);Solis-Pomales, C.(1);Ortiz-Domenech, S.(1);Marrero-Concepcion, F.(1);Marrero-Irizarry, J.(1);Torres, E.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P646: Will the screening of SARS-COV-2 infection in IBD infusion centers be useful?
Year: 2022
Source: ECCO'22
Authors: Abreu, N.(1);Oliveira, A.(1);Morna, H.(1);Jasmins, L.(1);
Created: Friday, 11 February 2022, 3:56 PM
P647 Post-marketing evaluation of reported adverse events of a multi-strain probiotic product confirms that change in manufacturing site had no impact on safety profile
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Panetta1, I. Simonelli1, A. Bacchieri2, S. Papetti3, E. De Stefani3, S. Colombo4

Created: Thursday, 30 January 2020, 10:12 AM
P647: A pilot study: The importance of cognitive flexibility and flexibility in coping with stress for the quality of life in inflammatory bowel disease patients during biological therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Rudnik*1,2, G. Piotrowicz2, M. Basińska3, G. Rydzewska4,5, V. Rashedi6,7

Created: Friday, 22 February 2019, 9:41 AM
P647: Awareness, knowledge and use of mesenchymal stem cells – a global survey among gastroenterologists and colorectal surgeons
Year: 2021
Source: ECCO'21 Virtual
Authors: Williams, P.(1);Klersy, C.(2);Karki, C.(3);Bennett, D.(3);Rodríguez, A.M.(4);Ciccocioppo, R.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P647: Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series
Year: 2022
Source: ECCO'22
Authors: Mahajna , H.(1);Verstockt , B.(2);Bergemalm , D.(3);Castiglione , F.(4);Rodríguez-Moranta , F.(5);Vincenzo Savarino , E.(6);Hoentjen , F.(7,8);Bessissow , T.(9);Pokryszka , J.(10);Cremer , A.(11);Eder , P.(12);Truyens , M.(13);Yershalmy-Feler , A.(14);García , M.J.(15);Kopylov , U.(1);
Created: Friday, 11 February 2022, 3:56 PM
P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Phillips1, R. Preskey2*, C. Penfold3, J. Tyrrell-Price1, F. Gordon4

Created: Thursday, 21 February 2019, 9:14 AM
P647: Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Almas, S.(1);Al-Talib, I.(1)*;Rahman, C.(1);Ansari, M.(1);Jones, J.(1);Slater, J.(1);King, D.(1);De Silva, S.(1);
Created: Friday, 14 July 2023, 11:12 AM
P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zerôncio M.*1, Blake A.2, Rana-Khan Q.3, Palo W.4, Bhayat F.5

Created: Wednesday, 20 February 2019, 10:36 AM
P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. WatanabeAssistant Professor1, M. Kawai2, R. Koshiba2, K. Fujimoto2, K. Kojima2, K. Kaku2, N. Kinoshita2, T. Sato1, K. Kamikozuru2, Y. Yokoyama2, T. Miyazaki2, N. Hida2, S. Nakamura2

Created: Thursday, 30 January 2020, 10:12 AM
P648: Anti-TNF-α therapy, use of corticosteroids, and colectomy among paediatric and adolescent patients with ulcerative colitis: a nationwide study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Lund*1,2, M. D. Larsen1, T. Knudsen3,4, J. Kjeldsen5,6, R. G. Nielsen7,8, B. M. Noergaard1,2

Created: Friday, 22 February 2019, 9:41 AM
P648: Clinical feasibility of dried blood sampling for infliximab in IBD patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Berends1,2*, G. D'Haens2, K. Bloem3,4, J. Schaap4, A. De Vries4, T. Rispens3,4, R. Mathôt1

Created: Thursday, 21 February 2019, 9:14 AM
P648: Effectiveness of Biologic Therapies in Decreasing Risk of Hospitalization and Surgery, Maintaining Steroid Free Remission and Achieving Mucosal Healing in Inflammatory Bowel Disease; Real World Data.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shehab, M.(1)*;Abdullah, I.(1);Alostad, W.(1);Marei, A.(1);Alfadhli, A.(1);
Created: Friday, 14 July 2023, 11:12 AM
P648: Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lindoso, L.(1);Oba, J.(1);Miranda, L.C.A.(1);Deboni, M.(1);Jiro Ozaki, M.(1);Lima, D.C.C.(1);Queiroz, L.B.(1);Astley, C.(2);Gualano, B.(2);Polanczyk, G.V.(3);K. Toma, R.(1);da Silva, C.A.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P648: Prevalence and Impact of Alcohol Consumption and Cannabis Use on Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Martinho-Grueber, M.(1);Kapoglou, I.(2);Bravo, F.(2);Sarraj, R.(2);Benz, E.(2);Restellini, S.(3);Biedermann, L.(4);Rogler, G.(4);Vavricka, S.R.(4);Schoepfer, A.(5);Maillard, M.(5);Michetti, P.(1);Brunner, F.(2);Clair, C.(6);Barry, M.P.(6);Von Kaenel, R.(7);JuilleratMSc, P.(2);
Created: Friday, 11 February 2022, 3:56 PM
P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Selinger C.*1, Lenti M.1, Clark T.1, Rafferty H.1, O'Connor A.1, Ahmad T.2, Hamlin J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P649 Dietary habits in patients with inactive Crohn’s disease: Results of a controlled study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Ben Mustapha, H. Ben Youssef, A. Labidi, M. Hafi, M. Fekih, M. Serghini, J. Boubaker

Created: Thursday, 30 January 2020, 10:12 AM
P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Visuri*1, C. Eriksson1, E. Mårdberg1, O. Grip2, A. Gustavsson3, H. Hjortswang4,5, P. Karling6, S. Montgomery7,8,9, P. Myrelid4,10, O. Olén9,11,12, The SWIBREG Study Group1, J. F. Ludvigsson13,14, J. Halfvarson1

Created: Friday, 22 February 2019, 9:41 AM